Teleflex Incorporated
TFXHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeTeleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the. At a $5.69B market cap, Teleflex Incorporated ranks as a mid-cap company within healthcare. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand.
Market Cap
$5.69B
Beta
0.81
P/E (TTM)
2144.00
P/E (Fwd)
12.30
EPS (TTM)
$0.06
EPS (Fwd)
$10.46
ROE
0.0%
ROA
2.3%
Cash
$333.1M
Total Debt
$2.74B
Free CF
-$3.7M
52W Change
7.5%
Annual Financials
Cash vs Debt
On the balance sheet, TFX has $333.1M in cash with $2.74B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$3.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 0.0%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.3% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $2.79B (2022) to $1.99B (2025), a 29% decline worth watching.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing TFX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.